|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||13.22 - 13.30|
|52 Week Range||11.00 - 20.64|
|Beta (3Y Monthly)||1.22|
|PE Ratio (TTM)||12.59|
|Forward Dividend & Yield||0.22 (1.57%)|
|1y Target Est||N/A|
Is Fresenius SE & Co. KGaA (FRA:FRE) a good dividend stock? How would you know? Dividend paying companies with growing...
Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday. Fresenius has hired Goldman Sachs to explore the sale, the people said.
Q1 2019 Update: Distributor Sales Take a Breather But Expected to Rebound. CytoSorbents (CTSO) reported financial results for their first quarter ending March 31st and provided a business update. While grant revenue was inline with expectations, product sales were a relative dud.
Germany is considering whether to impose a tax on carbon pollution or push to expand the existing European market in an effort to speed up the pace of reducing greenhouse gases. Chancellor Angela Merkel is calling for putting a price on the emissions from industries such as transport and buildings that are outside the European Union’s carbon trading program. It isn’t a matter of whether, but how Germany will make the move, she indicated in a little-reported April podcast.
Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.
On a per-share basis, the Bad Homburg, Germany-based company said it had net income of 50 cents. Earnings, adjusted for non-recurring costs, came to 59 cents per share. The dialysis services provider posted ...
Looking at Fresenius SE & Co. KGaA's (FRA:FRE) earnings update in December 2018, analyst forecasts seem fairly subdued, with earnings expected to grow by -7.2% in the upcoming y...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Every investor in Fresenius SE & Co. KGaA (FRA:FRE) should be aware of the most powerful shareholder groups. Insiders of...
Trade talks between the world's two biggest economies helped European shares rise on Wednesday, while the threat of a blocked merger sank shares in British supermarket Sainsbury's and a money laundering scandal hit Swedbank. Germany's trade-sensitive DAX led the way with a 0.8 percent gain and the pan-European STOXX 600 rose 0.7 percent after U.S. President Donald Trump said on Tuesday that trade talks with China were going well.
Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday. Investors, who were disappointed last year after the company trimmed its guidance in October and abandoned in 2020 targets in December, were heartened by the outlook and the prospect of a 7 percent increase in the dividend to 0.80 euros per share. "2019 will be a year of investment in growth areas such as home dialysis, biosimilars and new hospital services and therapies," Chief Executive Stefan Sturm said in a statement.
The U.S. Federal Trade Commission has given Germany's Fresenius Medical Care AG and U.S. home dialysis equipment maker NxStage Medical Inc antitrust approval for their merger, the agency said on Tuesday. To win approval for the $2 billion deal, the companies agreed to sell NxStage's bloodline tubing set business, the agency said. Fresenius and NxStage together dominate the market for the single-use plastic tubes used during dialysis, the agency said.
Want to help shape the future of investing tools? Participate in a short research study and receive a 6-month subscription to the award winning Simply Wall St research tool (valued Read More...
Attractive stocks have exceptional fundamentals. In the case of Fresenius SE & Co. KGaA (FRA:FRE), there's is a notable dividend-paying company with a a great history of performance, trading at Read More...
Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year. The warning letter, dated Friday, lists violations related to the agency's current good manufacturing practice regulations, which include poor aseptic behavior, as well as those related to environmental and personnel monitoring. The FDA said the company's response to its Form 483, which lists observations from the inspection in April and May, was inadequate.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
Moody's Investors Service ("Moody's") downgraded the ratings of Akorn, Inc. ("Akorn") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD and the senior secured term loan rating to Caa1 from B3. Moody's also downgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-2.
Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE. The move comes after the Delaware Supreme Court on Friday upheld a decision by a lower court to allow Fresenius to walk away from its over $4 billion acquisition of Akorn that sent shares of the U.S generic drugmaker down more than 30 percent in regular trading. Akorn said that its Chief Executive Officer Raj Rai will retire but will remain in his post till a successor is named.
Tobacco product Altria MO is buying a 45 percent stake in the cannabis producer for $1.8 billion. Big Lots BIG – The discount retailer l ost 16 cents per share for its latest quarter, wider than the one cent loss analysts were expecting. Revenue did beat forecasts, and a comparable store sales increase of 3.4 percent was above the consensus estimate of 2.9 percent.
Stephan Sturm, CEO of German health care firm Fresenius, breaks down the sales growth the company saw in the first quarter of 2019.